Edgewise TherapeuticsEWTX
EWTX
About: Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of treatments for severe, rare muscle disorders. It is developing orally bioavailable, small molecule therapies for musculoskeletal diseases. The company's product candidates are Sevasemten and EDG-7500. Sevasemten is an orally administered small molecule designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy (Duchenne) and Becker muscular dystrophy (Becker). The company is currently studying Sevasemten in Phase 2 trials, which are being held in the U.S. and Israel and in certain countries in Europe and Australasia.
Employees: 110
0
Funds holding %
of 7,419 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
137% more call options, than puts
Call options by funds: $23.3M | Put options by funds: $9.82M
125% more first-time investments, than exits
New positions opened: 45 | Existing positions closed: 20
16% more repeat investments, than reductions
Existing positions increased: 71 | Existing positions reduced: 61
13% more funds holding
Funds holding: 175 [Q3] → 198 (+23) [Q4]
13% more funds holding in top 10
Funds holding in top 10: 8 [Q3] → 9 (+1) [Q4]
2% less capital invested
Capital invested by funds: $2.7B [Q3] → $2.64B (-$62.3M) [Q4]
3.52% less ownership
Funds ownership: 108.05% [Q3] → 104.53% (-3.52%) [Q4]
Research analyst outlook
5 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$14
5%
upside
Avg. target
$38
186%
upside
High target
$52
291%
upside
5 analyst ratings
3 positive
60%
2 neutral
40%
0 negative
0%
Wedbush Laura Chico 9% 1-year accuracy 4 / 47 met price target | 223%upside $43 | Outperform Maintained | 21 Apr 2025 |
RBC Capital Leonid Timashev 12% 1-year accuracy 5 / 42 met price target | 291%upside $52 | Outperform Maintained | 3 Apr 2025 |
Scotiabank Louise Chen 19% 1-year accuracy 23 / 120 met price target | 5%upside $14 | Sector Perform Downgraded | 3 Apr 2025 |
Piper Sandler Yasmeen Rahimi 22% 1-year accuracy 5 / 23 met price target | 283%upside $51 | Overweight Maintained | 2 Apr 2025 |
Stifel James Condulis 33% 1-year accuracy 1 / 3 met price target | 126%upside $30 | Hold Initiated | 22 Jan 2025 |
Financial journalist opinion
Based on 9 articles about EWTX published over the past 30 days
Positive
Benzinga
1 week ago
Top 3 Health Care Stocks That Could Lead To Your Biggest Gains In Q2
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
Negative
24/7 Wall Street
1 week ago
These 5 Insiders Are Buying During Market Chaos
Market volatility has spiked since the beginning of April, due largely to uncertainty about inflation, interest rates, upcoming quarterly reports, and mostly the impact of tariffs and a global trade war on the U.S.
Negative
Zacks Investment Research
2 weeks ago
EWTX Stock Down 48% in a Week Despite Upbeat Cardiomyopathy Study Data
Edgewise Therapeutics stock plunges 48% in a week following safety concerns for its investigational hypertrophic cardiomyopathy treatment candidate, EDG-7500.
Positive
Seeking Alpha
2 weeks ago
Edgewise Therapeutics: Despite AF Safety Issues, EDG-7500 Advancement Presses On
The global hypertrophic cardiomyopathy market is expected to reach $1.35 billion by 2031. Despite a temporary stock drop due to adverse events and a $200 million stock offering, the long-term outlook for Edgewise Therapeutics, Inc. remains positive with multiple catalysts rapidly approaching for EWTX stock. Key milestones include 12-week data from the CIRRUS-HCM study in 2H 2025 and a phase 3 study initiation in 1H 2026.
Positive
Benzinga
2 weeks ago
Edgewise Therapeutics Sees Meaningful HCM Treatment Gains With EDG-7500 In Phase 2 Study
Edgewise Therapeutics, Inc., EWTX on Wednesday reported topline data of EDG-7500 from the Phase 2 CIRRUS-HCM four-week trial in participants with obstructive or nonobstructive Hypertrophic Cardiomyopathy (HCM).
Positive
Investors Business Daily
2 weeks ago
Why Edgewise Therapeutics And Cytokinetics Stocks Just Diverged
Shares of Edgewise Therapeutics and Cytokinetics diverged Wednesday after safety questions highlighted a heart disease study from Edgewise. The post Why Edgewise Therapeutics And Cytokinetics Stocks Just Diverged appeared first on Investor's Business Daily.
Neutral
PRNewsWire
2 weeks ago
Edgewise Therapeutics Announces Pricing of $200 Million Underwritten Offering of Common Stock
BOULDER, Colo. , April 2, 2025 /PRNewswire/ -- Edgewise Therapeutics, Inc. (NASDAQ: EWTX), a leading muscle disease biopharmaceutical company, today announced the pricing of an underwritten offering of 9,935,419 shares of its common stock at an offering price of $20.13 per share.
Neutral
PRNewsWire
2 weeks ago
Edgewise Therapeutics Announces Positive Top-Line Results from Phase 2 CIRRUS-HCM Four-Week Trial of EDG-7500 in Hypertrophic Cardiomyopathy (HCM)
– Phase 2 trial of EDG-7500 demonstrated rapid and clinically meaningful reductions in LVOT gradients in participants with obstructive HCM – – Four-week treatment with EDG-7500 demonstrated substantial improvements in measures of feel and function, reductions in key cardiac biomarkers and positive trends in measures of diastolic function – – EDG-7500 was generally well-tolerated; clinical activity was observed without meaningful changes in LVEF, including no participant with a value below 50% – BOULDER, Colo. , April 2, 2025 /PRNewswire/ -- Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced positive top-line data of EDG-7500 from the Phase 2 CIRRUS-HCM four-week trial in participants with obstructive or nonobstructive HCM.
Neutral
PRNewsWire
3 weeks ago
Edgewise Therapeutics to Host Webcast Event to Discuss Top-Line Results from Phase 2 CIRRUS-HCM 28-Day Trial of EDG-7500 in Hypertrophic Cardiomyopathy (HCM) on Wednesday, April 2 at 8:30 am Eastern Time
BOULDER, Colo. , March 26, 2025 /PRNewswire/ -- Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced that members of the management team will hold a live webcast to discuss top-line data of EDG-7500 from the Phase 2 CIRRUS-HCM 28-day trial in patients with obstructive or nonobstructive HCM on Wednesday, April 2, 2025, at 8:30 am ET.
Neutral
Business Wire
1 month ago
Edgewise Therapeutics to Present on Sevasemten for the Treatment of Becker Muscular Dystrophy at the 2025 MDA Clinical and Scientific Conference
BOULDER, Colo.--(BUSINESS WIRE)--Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced that the company will present data on sevasemten, an investigational orally administered first-in-class fast skeletal myosin inhibitor designed to protect against contraction-induced muscle damage, at the Muscular Dystrophy Association (MDA) Clinical and Scientific Conference. The conference will take place at the Hilton Anatole, Dallas, TX from March.
Charts implemented using Lightweight Charts™